- Home
- YCBD vs INM Comparison
YCBD vs INM Comparison
Compare YCBD & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YCBD | INM |
|---|---|---|
| Founded | 2015 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 7.1M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | YCBD | INM |
|---|---|---|
| Price | $0.45 | $1.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 347.7K | 52.7K |
| Earning Date | 08-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.11 | ★ 62.68 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,190,468.00 | $4,942,633.00 |
| Revenue This Year | $14.24 | N/A |
| Revenue Next Year | $30.43 | $26.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $0.41 | $0.58 |
| 52 Week High | $2.56 | $2.50 |
Technical Indicators
Market Signals| Indicator | YCBD | INM |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 44.37 |
| Support Level | $0.41 | $1.25 |
| Resistance Level | $0.53 | $1.40 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 24.71 | 35.28 |
Price Performance
Historical ComparisonAbout YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.